Uses
BMS 299897 is a known γ-secretase inhibitor that effectively reduces amyloid β-peptide (Aβ) in transgenic mice and guinea pigs (1,2,3). Studies have shown the possibility of using BMS 299897 in the treatments for Alzheimer’s patients.
Biological Activity
bms-299897 is a selective inhibitor of γ-secretase with ic50 value of 12 nm [1].γ-secretase is an intergral membrane protein whose well-known substrate is amyloid precursor protein and involves in the process of cleaving single-pass transmembrane proteins at residues with the transmembrane domain. it has been revealed thatγ-secretase cleave app in any of multiple sites and generate a 39 to 42 amino acids long peptide, among which aβ40 is the most common isoform and aβ42 is the most susceptible to conformational changes leading to amyloid fibrillogenesis. many studies have shown that reduction of brain aβ synthesis by gamma-secretase inhibitors is a promising approach for the alzheimer's disease treatment [1] [2].bms 299897 is a selective inhibitorγ-secretase. when tested hekwt culture with bms-299897, the expression of aβ(1-40) in culture supernatant had a robust rise throughγ-secretase inhibition [3].in male swiss mice model with intracerebroventricular (i.c.v.) injection of aβ(25-35) which induced alzheimer's disease pathomimetic toxicity, administration of bms-299897 markedly attenuated aβ(1-42)-whose accumulation marginally contributed to the toxicity or long-term memory deficits-seeding and toxicity induced by aβ(25-35) through inhibiting γ-secretase [4]. when tested with tg2576 mice, oral administration of bms-299897 markedly reduced abeta peptide concentrations by inhibitingγ-secretase [5] [2].
References
[1]. anderson, j.j., et al., reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors bms-289948 and bms-299897. biochem pharmacol, 2005. 69(4): p. 689-98.
[2]. barten, d.m., et al., dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. j pharmacol exp ther, 2005. 312(2): p. 635-43.
[3]. burton, c.r., et al., the amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. j biol chem, 2008. 283(34): p. 22992-3003.
[4]. meunier, j., et al., the gamma-secretase inhibitor 2-[(1r)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (bms-299897) alleviates abeta1-42 seeding and short-term memory deficits in the abeta25-35 mouse model of alzheimer's disease. eur j pharmacol, 2013. 698(1-3): p. 193-9.
[5]. goldstein, m.e., et al., ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in tg2576 mice. j pharmacol exp ther, 2007. 323(1): p. 102-8.
